Humacyte Q2 revenue $0.3M; 82 civilian hospitals now eligible to purchase Symvess; July sales exceed H1 total

Humacyte, Inc.

2025-Q2 EPS reported $0.01 revenue$818,000

Revenue $0.3M in Q2 (incl $0.1M Symvess sales); $0.8M in H1 2025 vs zero prior year.
82 civilian hospitals eligible to purchase Symvess (up from 5 in May); 13 VAC approvals covering multi-hospital networks.
ECAT approval makes Symvess available to ~35 Military Treatment Facilities and ~160 VA hospitals; first military sale in July followed by re-order.
Implemented workforce reduction of 30 employees; expects net savings ~$13.8M in 2025 and ~$38M in 2026.
Cash, cash equivalents, restricted cash $88.4M as of June 30; net cash used $6.9M in H1 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.